阿尔茨海默病和心血管遗传分数和认知:FINGER随机对照试验
Gazi Saadmaan1, Maria Carolina Dalmasso2,3, Maleeha Maria4
1Department of Neurology, Institute of Clinical Medicine, University of Eastern Finland, 70210 Kuopio, Finland.
Brain : a journal of neurology
|August 1, 2025
概括
对阿尔茨海默病或冠状动脉疾病有遗传倾向的个体可以从生活方式干预中受益. 这项研究发现,这些疾病的遗传风险评分 (GRS) 在FINGER试验中对认知产生了积极影响,特别是在女性中.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学 是一个
- 老年学是一门学科.
背景情况:
- 阿尔茨海默病 (AD) 和冠状动脉疾病 (CAD) 是老年人中普遍存在的慢性疾病.
- 分享的风险因素,如阿波利波蛋白E (APOE) ε4等位基因,链接AD和CAD.
- 以前的研究表明,多领域的生活方式干预可能为APOE4载体提供更大的认知益处.
研究的目的:
- 调查阿尔茨海默病 (AD-GRS) 和冠状动脉疾病 (CAD-GRS) 的遗传风险评分对FINGER试验中的认知结果的影响.
- 探索遗传风险是否影响多领域生活方式干预对认知的有效性.
主要方法:
- 这项研究分析了芬兰老年干预研究预防认知障碍和残疾 (FINGER) 试验的数据,该试验涉及1259名60-77岁没有痴呆症的参与者.
- 参与者被随机分配到为期2年的多领域生活方式干预或定期的健康咨询.
- 用全基因组关联研究 (GWAS) 数据计算遗传风险得分 (AD-GRS,CAD-GRS),并评估它们与认知变化的关联.
主要成果:
- 较高的AD-GRS和CAD-GRS与干预带来的更大的认知益处有关,尽管整体上不具有统计学意义.
- 在AD-GRS中观察到显著的性别差异,更高风险的女性从干预中表现出最实质性的认知改善.
- 对CAD-GRS的基因风险较高和较低的群体,干预对认知的影响相似.
结论:
- 多领域的生活方式干预表明,对那些对阿尔茨海默氏症和冠状动脉疾病有遗传易感性的个体有潜在的益处.
- 遗传风险评分可以帮助识别那些特别受益于旨在维护认知功能的生活方式干预措施的人.
- 需要对更大,更多样化的群体进行进一步的研究,以证实这些探索性发现,并了解性别特异性的影响.
相关概念视频
Alzheimer's Disease: Overview
669
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
669
Alzheimer's Disease: Treatment
262
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
262
Atherosclerosis III: Management
35
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
35
Dementia
166
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
166
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
40
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
40
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
337
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
337


